September 2022 in “Research, Society and Development” Long-lasting symptoms like fatigue and breathlessness can persist after COVID-19, requiring ongoing medical follow-up.
September 2022 in “bioRxiv (Cold Spring Harbor Laboratory)” Hair follicles and urine cell pellets are promising for transcriptome studies due to consistent quality and useful expression profiles.
July 2021 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” Monilethrix causes different levels of hair loss in family members.
January 2020 in “JAAD case reports” Hair loss condition FFA was seen before the appearance of skin depigmentation vitiligo in a patient.
November 2019 in “BMC veterinary research” The hair loss in Belgian Blue crossbred calves was caused by a diet issue, not by disease or infection.
April 2019 in “Journal of the Endocrine Society” Using LC-MS/MS for hormone measurement can prevent false high testosterone results and avoid unnecessary tests.
Microneedling and PRP are generally safe but can cause mild skin issues; serious problems are rare.
January 2017 in “Journal of Investigative Dermatology Symposium Proceedings” The 2015 Hair Research Congress concluded that stem cells, maraviroc, and simvastatin could potentially treat Alopecia Areata, topical minoxidil, finasteride, and steroids could treat Frontal Fibrosing Alopecia, and PTGDR2 antagonists could also treat alopecia. They also found that low-level light therapy could help with hair loss, a robotic device could assist in hair extraction, and nutrition could aid hair growth. They suggested that Alopecia Areata is an inflammatory disorder, not a single disease, indicating a need for personalized treatments.
January 2016 in “Hematology & Transfusion International Journal” Platelet Rich Plasma (PRP) injections can improve hair count, thickness, and strength in people with androgenic alopecia.
September 2004 in “PubMed” Androgenetic alopecia, or hair loss, is influenced by hormones and genetics, and can be treated with medications like minoxidil, finasteride, or hormone therapy, with effectiveness evaluated after 6 months.